Skip to main content

Table 3 Adjusted association between hepatic adverse events and episodes groups in the AL arm

From: Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso

Parameters aOR (95% CI) with hepatic adverse events
Elevated ALT
LR-p value: 0.025
Elevated AST
LR-p: <0.001
Elevated total bilirubin
LR-p: 0.001
Episode groups    
 First treatment 1 1 1
 Retreatment 0.24 (0.08; 0.70) * 0.16 (0.06; 0.41) *** 2.48 (1.31; 4.69) **
Age 0.96 (0.87; 1.05) 0.83 (0.73;0.93) ** 1.05 (1.02; 1.09) **
Sex    
 Female 1 1 1
 Male 1.96 (0.67; 5.77) 0.80 (0.34; 1.84) 1.04 (0.61; 1.75)
  1. AL: artemether–lumefantrine; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; LR-p: likelihood ratio test’s p-value; aOR: adjusted odds ratio; CI: Confidence interval;
  2. * p < 0.05; ** p < 0.01; *** p < 0.001